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BAckground: Cancer is one of the most prevalent diseases in the UK with over 
300,000 cases every year, with breast cancer being the most common cause of 
death for adults aged 35-64.48% of all diagnosed with cancer die within 5 years. 
Cancer puts huge cost pressure on NHS resources. Multi-staged drug therapies 
involve the use of drugs to either slow down the proliferation of cancer cells or 
kill them, with variable success. The new innovative drugs are deemed to be too 
expensive for the limited benefit they may offer as the cancer may have reached 
terminal stage, after an already expensive overall course of therapy. oBjectives: 
to perform a systematic review and meta-analysis to investigate whether the drug 
cost is the main driver for the high Incremental Cost utility ratios. Methods: 
Systematic review and meta-analysis were performed to answer the research 
question. The search was concentrated to the drugs of the three most common 
cancers in the UK (breast, lung and prostate). Cardiff search database was used 
to perform the search. Two independent reviewers screened papers for inclusion, 
extracted data, and assessed the quality of reviews. PRISMA checklist was used 
by the author to undertake the meta-analysis. results: 146 publications were 
retrieved. Final number of publications included went down to 14 [The PRISMA 
scoring for 71% of them (10 publications) were 21-24/27]. From which 25 cost 
effectiveness studies were extracted. Not every oncology drug showed high ICER 
(above £30 000), only 10 studies (45% of the publications), which contradicts the 
common perception about ICERs of oncology. More surprisingly was that eight 
(80%) of the 10 studies showed moderate cost per treatment. conclusions: Cost 
of drug treatments is not the main driver for the high ICER (P-value: 0.982) but it 
is one of many that heavily impact the ICER value.
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oBjectives: Risk stratification based on results provided by a 21-gene assay 
(Oncotype DX ®) in early stage breast cancer can help to optimize hormone therapy 
(HT) and chemotherapy (CT) decisions, by stratifying women according to recurrence 
risk. Previous reviews addressing the issue were outdated or did not provide data on 
both overall and net decision impact regarding use of CT in this group of women. We 
aimed to perform a systematic review and meta-analysis on global decision impact 
and net change in CT use by risk category before and after assay results. Methods: 
We updated a broader systematic review (Carlson, search up to 03/12). Inclusion 
criteria were further restricted to studies with prospective data collection. Global 
decision impact was estimated as the proportion of patients whose management 
was changed after assay results were available. Net change was estimated as the 
difference between the proportion of all patients who received chemotherapy before 
and after the test. results: Ten studies (N= 1218) met our inclusion criteria; 49.75, 
38.18 and 12.07% of patients were low, intermediate and high risk. Due to significant 
heterogeneity among studies, a random effects model is presented. Treatment deci-
sion was changed in 30.83% (95% CI 26.75 to 35.07) of all patients. From all patients, 
net change of CT use was 16% (95%CI 12-20) in the low risk group (CT+HT to HT); 
0% (-4 to 3) in the intermediate risk; and -2% (-3 to -1) in the high risk group, in this 
latter case increasing CT use (HT to CT+HT). conclusions: Using a 21-gene assay 
showed a significant impact on treatment decisions (from 100 women, 31 will have 
their treatment optimized, and 14 less net CT overall). Its main effects consist of 
sparing chemotherapy in low risk patients, and increasing it in the high risk category.
PCN275
towarDs a fraMework for aNalysiNg sustaiNaBility of eCoNoMiC 
value: the Case of a short stay PrograMMe for Breast CaNCer 
surgery Care five years after iMPleMeNtatioN
Ament S.1, Gillissen F.1, Maessen J.2, van der Weijden T.3, von Meyenfeldt M.2, Dirksen C.D.4
1Maastricht University, Maastricht, The Netherlands, 2Maastricht University Medical Centre, 
Maastricht, The Netherlands, 3Department of Family Medicine, CAPHRI School for Public Health 
and Primary Care’, Maastricht University, the Netherlands, Maastricht, The Netherlands, 
4Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University 
Medical Centre, Maastricht, The Netherlands
oBjectives: Critical analysis of sustainability of health care innovations is a rela-
tively new concept. The aim of this study was to provide an analytical framework 
for the evaluation of sustainability of economic value in health care. The application 
of the framework was demonstrated by using an exemplary case on a short stay 
programme for breast cancer surgery care (SSP) in the Netherlands. Methods: 
Sustainability of economic value was determined in terms of the incremental net 
monetary benefit (iNMB), in this case, five years after the end of active implementa-
tion (LATE POST) compared to early post-implementation results (POST). Economic 
value was evaluated as fully sustained if the iNMB equalled zero or was positive. 
Value of sustainability was present if the iNMB was negative. Cost and effective-
ness data of the primary implementation study were used for the POST group. The 
same data collection method was used to determine the NMB of the LATE POST 
group. results: Economic value of the SSP was fully sustained as the mean pooled 
iNMB was € 1648 per patient. A stepwise multi-regression analysis showed that, after 
adjustment for age, NMB was higher in the LATE POST group compared to the POST 
group (B= € 1162, SE= € 714, p= 0.105, adjusted R2= 0.065). The level of sustainability 
of economic value varied between hospitals. conclusions: The current study 
presented an analytical framework for the analysis of sustainability of economic 
value. The proposed framework provides guidance to analyse the sustainability of 
the economic value achieved in the post-implementation phase. Application of the 
framework raised issues as when to perform the analysis, the appropriate perspec-
oBjectives: In many European jurisdictions relative effectiveness assessments 
(REAs) of pharmaceuticals are performed as part of the reimbursement decision 
making process. Collaboration in the production of these assessments across 
jurisdictions prevent duplication of information in various jurisdictions and save 
resources accordingly. A first pilot of a joint REA of pharmaceutical (pazopanib 
for the treatment of renal cell carcinoma) was published in 2011. The aim of this 
study is to verify how informative the joint REA is for national assessments by 
comparing the joint REA of pazopanib with nationally produced assessments on 
the same topic. Methods: National assessments from European countries were 
identified through a literature search and an email request to health technology 
assessment (HTA) organisations. Data were abstracted from the assessments using 
a structured data abstraction form including questions about the criteria assessed, 
the scope, the evidence included, the assessment of the evidence and the outcome 
of the assessment. The abstracted data were validated by representatives from the 
authoring organisations. results: In total five jurisdiction specific HTA reports, 
available in English language, were included (Belgium, England/Wales, France, The 
Netherlands and Scotland). Four out of five reports included a positive recommen-
dation on pazopanib. Although the general methods (indication, main comparator, 
main endpoints, main trial) were similar the details of the assessment (e.g. exact 
wording of indication, additional comparators, additional trials included, method 
of indirect comparison) varied. The joint REA included nearly all of the compara-
tors, endpoints, trials and methods of analysis that were used in the jurisdiction 
specific REA reports. conclusions: Although there is some variety in the number 
of comparators and methods for analysis for the included jurisdiction specific REA 
reports on pazopanib, it seems feasible to capture most of these in an extensive joint 
REA. This suggests that joint REAs may serve their role as a basis for national REAs.
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oBjectives: Human Epididymis Protein 4 (HE4) is diagnostic test that diagnosis 
ovarian cacner with CA125 for pelvic mass patients or monitoring of response to 
treatment, prognosis and reccurence for ovarian cancer patients. So We assess the 
safety and efficacy of HE4 test. Methods: We searched eight domestic databases and 
other foreign databases such as Ovid-MEDLINE, Ovid-EMBASE, and Cochrane Library. 
The 44 articles were included in this review. Two reviewers independently assessed 
selection of studies and quality assessment of each study. Quality assessment tool 
was used SIGN. The meta analysis results reported pooled sensitivity and specificity.  
results sAFetY: HE4 was conducted with patient’s serum sample, so safety is same 
as a blood sampling. Thererfore, there is no safety problem. EFFICACY: 1) HE4 vs 
CA125: In 10studies, the pooled sensitivity and specificity were HE4 0.771, 0.931 and 
CA125 0.839, 0.677.6 studies with suspected ovarian cancer were included, pooled 
sensitivity and specificity were HE4 0.745, 0.946, CA125 0.819, 0.676. In two studies, 
hazard ratio of progression-free survival and overall survival for HE4 were higher 
than CA125.2) ROMA vs CA125: In 6studies, the pooled sensitivity and specificity were 
ROMA 0.865, 0.809 and CA125 0.843, 0.672. Three studies with suspected ovarian can-
cer were included, pooled sensitivity and specificity were ROMA 0.833, 0.857, CA125 
0.817, 0.664. In one study, hazard ratio of progression-free survival and overall survival 
for ROMA were higher than CA125. conclusions: Although sensitivity of HE4 was 
lower than CA125, but specificity was higher than CA125. So HE4 supplemented lower 
specificity of CA125. Beause sensitivity and specificity of ROMA were highter than 
CA125, lower sensitivity of HE4 were supplement with CA125. Also prognostic value 
of this test looks like it can be used to predict recurrence in patients diagonised with 
epithelial ovarian cancer, it’s hard to generalize it will current research outcomes.
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oBjectives: In Germany third parties like manufacturers, physician associations, 
medical societies, or industry organisations are allowed to comment on the early 
benefit assessments (EBA) of drugs by submitting written statements (WS) and 
attending oral hearings (OH) before the Federal Joint Committee (G-BA) decides on 
a resolution. This review assesses the number of WS and OH participants of cancer 
drugs’ EBA and evaluates trends in third party participation (TPP). Methods: The 
status of cancer drugs’ EBA and associated documents from 2011 until May 2014 
were retrived from the G-BA website. All completed assessments were included if 
a summary documentation including the OH protocoll and all WS was available. 
Information on number and category of third parties submitting WS or attend-
ing OH were extracted from the summary documentation, categorized and ana-
lysed. results: Until May 2014 28 cancer drugs’ EBA were started and 25 completed. 
Summary documentation was available for 14 (56%) completed assessments. The 
mean number of submitted WS was 9.1 (range 4-16). The mean number of third 
parties in OH was 5.9 (range 3-9). In all EBA the manufacturer submitted WS and 
participated in the OH. Representatives of at least one competitor and pharmaceu-
tical industry organizations each were present in all OH. Apart from one EBA, for 
which no dossier was available, medical societies always turned in WS and attended 
11 (85%) OH. In the beginning of the EBA process the number of submitted WS was 
slightly higher. Overall, no trend for TPP in OH was identified. conclusions: In 
Germany TPP in cancer drugs’ EBA is broadly used by both medical societies and 
the pharmaceutical industry. Further research is required to identify reasons why 
medical societies do not attend OH although a WS was handed in.
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elderly. Of these patients, 31% received chemotherapy, 35.5% radiotherapy, and 10% 
both. The proportions of elderly patients receiving chemotherapy, radiation therapy, 
or both, remained stable throughout the study period. The most common indica-
tions for which elderly patients received chemotherapy included gastrointestinal 
(39%), lung (15%), breast (12%), and head and neck (9%) cancers. Overall, 17% of 
the elderly patients received > 2 lines of chemotherapy protocols; a similar rate 
(16%) was observed in the subgroup of patients ≥ 85 years of age. conclusions: 
Approximately 30% of the cancer population treated in a large tertiary cancer center 
were elderly patients (≥ 75 years of age). The findings of this study may promote a 
discussion regarding medical resources, staff training, and planning a designated 
evaluation for geriatric cancer patients that should include special consideration 
to the patients’ comprehensive functioning.
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oBjectives: To describe systemic treatment of metachronous metastases and 
the reasons of not receiving systemic treatment in patients with breast cancer.  
Methods: Patients diagnosed with breast cancer without metastasis at initial diag-
nosis (M0) between 2006-2008 were selected from the Eindhoven Cancer Registry. 
By means of active follow-up by the Cancer Registry staff until January 2012, data 
on development of metastatic disease, treatment, and reasons of not receiving sys-
temic treatment were collected directly from the patient files. results: Of 1,382 
patients diagnosed with M0 breast cancer, 116 (8%) developed metachronous metas-
tases during a median follow-up of 4.4 years. Of the patients developing metachro-
nous metastases, 86 (74%) patients received systemic treatment with a median (± 
SD) age of 59.7 (± 13.4) years. Of these, 46 patients (53%) received chemotherapy, 19 
patients (22%) received hormonal therapy and 21 patients (24%) received a combi-
nation of chemotherapy and hormonal therapy. Median (± SD) age of the patients 
who did not receive systemic treatment (n= 30) was 70.0 (± 15.9) years. Of the 67 
patients receiving chemotherapy, 17 patients (25%) were treated with taxane con-
taining chemotherapy as first-line treatment. Of the 30 patients without any sys-
temic treatment, 10 patients received radiotherapy, 3 patients underwent surgery 
and 6 patients refrained from systemic treatment. Other reasons for not receiving 
systemic treatment were: extensiveness of metastases/life expectancy (n= 4), death 
before first application of chemotherapy (n= 4), high age (n= 1), comorbidities (n= 1) or 
bad experience with chemotherapy in the past (n= 1). conclusions: Of the initially 
M0 breast cancer patients who developed metastases during follow-up the majority 
received systemic treatment. A quarter of the patients did not receive systemic treat-
ment, primarily due to other treatment policies, refraining from treatment or poor 
condition. This study provides more insight into the treatment of metachronous 
metastases in the Netherlands.
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oBjectives: To describe current guidance on BRCA testing practices in patients 
with ovarian cancer (OC) in China, European countries, and US. Methods: 
Guideline databases like National Guideline Clearinghouse, Guidelines 
International Network, and National Institute for Health and Care Excellence 
were searched for guidelines in both ovarian and breast cancer. Additionally, 
relevant medical societies like United States Preventive Services Task Force, 
National Society of Genetic Counselors, American Society of Clinical Oncology, 
European Society for Medical Oncology, European Society of Human Genetics, 
Chinese Society of Clinical Oncology, Chinese Academy of Medical Sciences, and 
International Cancer Genome Consortium were considered. Guidelines were 
included if they contained recommendations for BRCA testing in OC or patient 
characteristics for BRCA mutation in OC, were published after 2003, were cur-
rently valid, and published in English, Chinese or German language. results: The 
search revealed a total of 22 guidelines. Ten breast cancer guidelines were excluded 
because they did not add any information beyond that found in guidelines for OC. 
Ten out of 12 guidelines recommend genetic testing for healthy individuals with 
familial history of ovarian or breast cancer and a personal history of breast cancer. 
Most guidelines differ in their description of selection criteria such as degree of 
relationship between affected individuals and counselee, age at diagnosis, and 
individual history of early onset cancer. Five out of 12 guidelines also recommend 
screening for patients of Jewish Ashkenazi or Icelandic descent. conclusions: 
Current guidance recommends genetic testing primarily for healthy individuals; 
a few guidelines recommend testing in diagnosed ovarian cancer patients. Using 
current recommendations a substantial number of patients with OC due to an 
inherited BRCA mutation are missed. With options for treatment aimed at muta-
tion carriers, identification of all OC patients with BRCA mutation will facilitate a 
personalized therapy and identify family members at risk of cancer.
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tive and level of analysis (macro or meso level), and whether regression correction 
should be performed. A limitation of the illustrative case study was that costs of 
sustainability activities were not collected.
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oBjectives: To critically assess cost-sharing schemes between payers and market-
ing authorization holders (MAHs) that are in some jurisdictions used as a means to 
control public spending on prescription drugs. Methods: Cost-sharing scheme can 
be theoretically expressed as the two-step process, where the discount of the MAH 
equals p when x≤ n, and 0 when x> n, where n is the number of weeks/months with 
reduced price of a drug and x is the length of treatment in weeks/months. Within 
such a scheme, the overall discount has no lower limit as it is inversely proportional 
to x, i.e., np/x. Payers and MAHs may estimate and agree upon the expected length 
of treatment x= m0 based on, e.g., randomized clinical trials (RCTs); however, these 
estimates may be unreliable due to, inter alia, market power of MAHs that could 
influence prescribers to select those patients that will remain longer on the treat-
ment. results: Two-step cost-sharing scheme results in the effective discount that 
is lower than expected discount by (x-m0) /x, once x surpasses m0. The lower limit 
of the discount can be achieved if the two-step cost-sharing scheme is modified 
by an additional step: the discount then equals (i) p when x≤ n, (ii) 0 when m0≥ x> n, 
and (iii) np/m0 when x> m0. Cost-sharing scheme in this format guarantees that the 
effective discount remains at the expected level of np/m0 and gives no incentive 
to MAHs to exert their market power and prolong treatment duration. We applied 
our simple model to a real-life case of innovative oncological drug (p= 100%; n= 6 
weeks; m0= 30 weeks). conclusions: We have shown that cost-sharing schemes 
should incorporate an additional step in order to ensure the effective control of 
expenditure for drugs. This finding may be of value to those jurisdictions that resort 
to cost-sharing as a tool in curtailing prescription drug costs.
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oBjectives: Limited data regarding effectiveness, efficacy, safety or cost-effective-
ness at marketing authorization reflect uncertainties that payers try to counteract 
with performance-based risk-sharing arrangements (PBRSAs). PBRSAs link medi-
cines’ reimbursement to health outcomes and seem to reduce these uncertainties 
– especially for stratified medicine in oncology. We wanted to identify PBRSAs for 
stratified medicine in oncology to discuss advantages, disadvantages, their cost-
effectiveness and whether they could reduce uncertainties. Methods: A litera-
ture search was conducted in bibliographical databases from 2003-2013. Searching 
websites of reimbursement bodies from Australia, Canada, Germany, UK, USA and 
hand searching completed the search strategy. Publications were eligible if reim-
bursement for stratified medicine in oncology was linked to health outcomes. 
A self-developed checklist based on ISPOR Task Force Report on PBRSAs (Garrison 
et al., [Value Health. 2013; 16 (5): 703-19]) was used to conduct quality assessment. 
This checklist consists of five domains assessing the quality of a PBRSA: descrip-
tion, desirability and rationale, implementation, evidence collection and evalua-
tion. results: We identified 43 publications resulting in 40 PBRSAs (Canada: 12, 
Italy: 9, UK: 7, Australia: 8, The Netherlands: 2, USA: 1, Slovenia: 1). Most schemes are 
related to leukemia (mainly dasatinib, imatinib and nilotinib). These PBRSAs were 
categorized in subcategories: risk sharing schemes (RSS) such as ‘outcomes guar-
antees’ (n= 7), ‘conditional treatment continuation’ schemes (n= 22), ‘money back 
guarantees’ (n= 3) and coverage with evidence development schemes (CED) such as 
‘only in research’ schemes (n= 8). Quality assessment was limited by lack of reporting 
on PBRSAs’ details. Therefore, ambiguity remains about PBRSAs’ cost-effectiveness 
and their reduction of uncertainties. conclusions: RSS provide faster access to 
therapies, guarantee reimbursement for manufacturers and possibly cost contain-
ment for payers, but do not necessarily collect additional evidence. The administrative 
burden and related costs appear to be huge. Existing value of information analysis 
approaches were not applied to CED schemes. Evaluations of PBRSAs are necessary 
to assess their value.
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oBjectives: Primary: To describe the use of anti-cancer treatments in elderly 
patients (≥ 75 years of age) at the Davidoff Center between 2006 and 2013. Secondary: 
To investigate the correlations between anti-cancer treatments and socio-demo-
graphic- and cancer-related parameters. Methods: The analysis included all 
elderly (≥ 75 years) cancer patients treated at the Institute of Oncology, Davidoff 
Center between 2006 and 2013. The analysis included Israeli residents (i.e., “medical 
tourists” were excluded). Patients who were treated elsewhere and had a single con-
sultation appointment at the Davidoff Center were also excluded from the analysis. 
The following parameters were assessed: demographic variables, cancer diagnosis, 
chemotherapy and radiation treatments received, clinic visits, hospitalizations, and 
the utilization of other health-related services. results: Out of 21,009 new patients 
treated at the Davidoff Center between 2006 and 2013, 6, 553 patients (31%) were 
